Catalysing Growth in the Life Sciences Industry
Cambridge, 26th-27th April, Exonate’s CEO Dr Catherine Beech and COO Dr Loic Lhuillier are pleased to attend BioTrinity an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry.
The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.
CEO, Dr Catherine Beech and COO, Dr Loic Lhuillier are available for meetings, contat can be made via Sarah Buchallet firstname.lastname@example.org
Sarah Buchallet, Marketing
Catherine Beech, CEO Tel: +44 (0) 1223 734710
Exonate are using the mRNA blueprint as a therapeutic formula to instruct cells in how to treat diseases. Leveraging our expertise in the alternative mRNA splicing of Vascular Endothelial Growth Factor (VEGF) we have developed a pipeline of small molecule drugs for the treatment of patients with chronic diseases
Exonate’s lead compound, formulated to be delivered topically with eye drops, is now in Phase 1 clinical trials for the treatment of centre-involved diabetic macular oedema. The clinical trial is in collaboration with Janssen Pharmaceuticals, Inc., and built upon extensive pre-clinical work supported by previous investments. Having relocated to larger research labs at MediCity we are continuing our pre-clinical mRNA-targeting research focusing on ophthalmology and renal disease.